Erectile Dysfunction - Pipeline Review, H2 2018

Date: July 17, 2018
Pages: 118
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until August 3, 2018!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: EE05B3281FCEN
Leaflet:

Download PDF Leaflet

Erectile Dysfunction - Pipeline Review, H2 2018
Erectile Dysfunction - Pipeline Review, H2 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H2 2018, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 2, 6, 6, 1, 12, 2 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Global Markets Direct Report Coverage
Erectile Dysfunction - Overview
Erectile Dysfunction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Erectile Dysfunction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Erectile Dysfunction - Companies Involved in Therapeutics Development
Apricus Biosciences Inc
Aquestive Therapeutics Inc
Astellas Pharma Inc
Biolab Farmaceutica Ltda
Biopharm GmbH
Biozeus Pharmaceutical SA
Can-Fite BioPharma Ltd
Fabre-Kramer Pharmaceuticals Inc
Futura Medical Plc
Humanetics Corp
IntelGenx Corp
Ion Channel Innovations LLC
Karessa Pharma Holding AB
Mezzion Pharma Co Ltd
Mitsubishi Tanabe Pharma Corp
N4 Pharma Plc
NAL Pharmaceuticals Ltd
Pharmicell Co Ltd
SK Chemicals Co Ltd
Suda Pharmaceuticals Ltd
XuanZhu Pharma Co Ltd
Yangtze River Pharmaceutical Group
Erectile Dysfunction - Drug Profiles
(finasteride + tadalafil) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alprostadil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-185 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avanafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BL-214 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BZ-371 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellgram-ED - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FKK-01PD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPED-2015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
libiguins - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MED-2002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MED-2005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirabegron ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pVAX-hSlo - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PDE5 for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUD-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-6932 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TF-0092 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPN-729 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TR-399 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
udenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vardenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XZP-5849 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Yonkenafil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Erectile Dysfunction - Dormant Projects
Erectile Dysfunction - Discontinued Products
Erectile Dysfunction - Product Development Milestones
Featured News & Press Releases
Jun 26, 2018: Initiator Pharma announces MHRA approval for clinical trial
Jun 19, 2018: iX Biopharma Obtains Approval and Registration of Wafesil for the Treatment of Male Erectile Dysfunction in Australia
Jun 04, 2018: Initiator Pharma selects Clinical Site
May 02, 2018: Best in Class Erectile Dysfunction Drug - DRGT announces dose escalation study results of its Super-Tadalafil DRGT-99
Jan 22, 2018: Initiator Pharma successfully completes the preclinical development of its Erectile Dysfunction drug candidate IPED2015 ahead of time
Jan 04, 2018: Potential Breakthrough Treatment for Erectile Dysfunction
Dec 15, 2017: Initiator Pharma reports positive results from the 28 days toxicology study in mini-pigs for its lead drug candidate IPED2015
Nov 22, 2017: Initiator Pharma receives positive result from the toxicology and toxicokinetic studies for its lead drug candidate IPED2015
Oct 31, 2017: Humanetics Presents Data on Potential Treatment to Prevent Erectile Dysfunction in Prostate Cancer Patients
Oct 26, 2017: Initiator Pharma initiates toxicology and toxicokinetic studies for its lead drug candidate IPED2015
Oct 10, 2017: N4 Pharma: Sildenafil PCT Update
Sep 07, 2017: A busy summer is providing valuable and Positive Results from the first Maximum tolerated dose toxicology for drug Candidate IPED2015
Aug 23, 2017: iX Biopharma Provides Update on PheoniX
Jul 27, 2017: N4 Pharma: Filing of Patents and Sildenafil Update
Jul 27, 2017: N4 Pharma: Update on Sildenafil clinical plans
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Erectile Dysfunction, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Erectile Dysfunction - Pipeline by Apricus Biosciences Inc, H2 2018
Erectile Dysfunction - Pipeline by Aquestive Therapeutics Inc, H2 2018
Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H2 2018
Erectile Dysfunction - Pipeline by Biolab Farmaceutica Ltda, H2 2018
Erectile Dysfunction - Pipeline by Biopharm GmbH, H2 2018
Erectile Dysfunction - Pipeline by Biozeus Pharmaceutical SA, H2 2018
Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H2 2018
Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2018
Erectile Dysfunction - Pipeline by Futura Medical Plc, H2 2018
Erectile Dysfunction - Pipeline by Humanetics Corp, H2 2018
Erectile Dysfunction - Pipeline by IntelGenx Corp, H2 2018
Erectile Dysfunction - Pipeline by Ion Channel Innovations LLC, H2 2018
Erectile Dysfunction - Pipeline by Karessa Pharma Holding AB, H2 2018
Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H2 2018
Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018
Erectile Dysfunction - Pipeline by N4 Pharma Plc, H2 2018
Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H2 2018
Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H2 2018
Erectile Dysfunction - Pipeline by SK Chemicals Co Ltd, H2 2018
Erectile Dysfunction - Pipeline by Suda Pharmaceuticals Ltd, H2 2018
Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H2 2018
Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, H2 2018
Erectile Dysfunction - Dormant Projects, H2 2018
Erectile Dysfunction - Dormant Projects, H2 2018 (Contd.1), H2 2018
Erectile Dysfunction - Dormant Projects, H2 2018 (Contd.2), H2 2018
Erectile Dysfunction - Discontinued Products, H2 2018

LIST OF FIGURES

Number of Products under Development for Erectile Dysfunction, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Apricus Biosciences Inc
Aquestive Therapeutics Inc
Astellas Pharma Inc
Biolab Farmaceutica Ltda
Biopharm GmbH
Biozeus Pharmaceutical SA
Can-Fite BioPharma Ltd
Fabre-Kramer Pharmaceuticals Inc
Futura Medical Plc
Humanetics Corp
IntelGenx Corp
Ion Channel Innovations LLC
Karessa Pharma Holding AB
Mezzion Pharma Co Ltd
Mitsubishi Tanabe Pharma Corp
N4 Pharma Plc
NAL Pharmaceuticals Ltd
Pharmicell Co Ltd
SK Chemicals Co Ltd
Suda Pharmaceuticals Ltd
XuanZhu Pharma Co Ltd
Yangtze River Pharmaceutical Group
Skip to top


Ask Your Question

Erectile Dysfunction - Pipeline Review, H2 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: